Home|Journals|Articles by Year Follow on Twitter

Directory for Medical Articles

Open Access

Review Article

IJMDC. 2020; 4(11): 1993-1995

Sodium-glucose cotransporter 2 inhibitor effects on cardiovascular outcomes: a short review

Ibrahim Mahmoud H Ajwah, Waleed Jamal Aloqbi, Ahmed Ebrahim Al Ansari, Nawaf Saeed Almalki, Abdulelah Hamdan Alonizei, Razan Faisal Aljohani, Omniyyah Ahmed Alnahyah, Razan Kamel Albalawi, Sultan Makki Alsharef, Abdulrahman Abdulhadi Alatawi, Afnan Mohammed Almutairi, Wedad Eid Aljthli, Amirah Naif Albalawi, Mohammed A. Alotaibi, Mohammed Abdullah Alasmari, Atheer Hammad Alatawi.

Type 2 diabetes is a chronic and progressive disease associated with a series of complications, including major
adverse cardiovascular events. As adequate glycemic control has been proven to reduce this risk, sodium-glucose
cotransporter 2 (SGLT2) inhibitors are among the promising medications in managing patients with type
2 diabetes. The current systematic review aimed to explore the SGLT2 inhibitor effects on cardiovascular outcomes.
A filtration procedure was used to remove duplicates and irrelevant publications. The online databases such as PubMed, Google Scholar, and EBSCO were used to perform a literature search, without any date or language restrictions. We used a combination of relevant search terms “diabetes, sodium-glucose cotransporter 2 inhibitors, and cardiovascular." We independently identified publications and systematically screened titles, abstracts, and full texts of the collected publications. Among 200 articles initially selected based on the title and abstract, 197 articles were excluded. Finally, three articles were selected and included in the review. All three studies concerned about the cardiovascular safety of SGLT2 inhibitors and showed that, compared with placebo, empagliflozin, canagliflozin, and dapagliflozin safely lower blood glucose with a reduction in the major adverse cardiovascular events. Across the three trials, empagliflozin, canagliflozin, and dapagliflozin resulted in a consistent class effect on cardiovascular outcomes.

Key words: Cardiovascular events, SGLT2 inhibitor, diabetes.‎

Similar Articles

Hyperglycemia in acute ischemic stroke: physiopathological and therapeutic complexity.
Ferrari F, Moretti A, Villa RF
Neural regeneration research. 2022; 17(2): 292-299

A not so perfect plan: An examination of the differential influence of multidimensional perfectionism on missed and gained events during the COVID-19 pandemic.
Levine SL, Andrade G, Koestner R
Personality and individual differences. 2022; 184(): 111214

Baculoviral inhibitor of apoptosis protein repeat-containing protein 3 delays early Wallerian degeneration after sciatic nerve injury.
Cai M, Shao J, Yung B, Wang Y, Gao NN, Xu X, Zhang HH, Feng YM, Yao DB
Neural regeneration research. 2022; 17(4): 845-853

Stroke recovery enhancing therapies: lessons from recent clinical trials.
Rogalewski A, Schäbitz WR
Neural regeneration research. 2022; 17(4): 717-720

Assessment of structural brain changes in patients with type 2 diabetes mellitus using the MRI-based brain atrophy and lesion index.
Zhao H, Wang F, Luo GH, Lei H, Peng F, Ren QP, Chen W, Wu YF, Yin LC, Liu JC, Pan SN
Neural regeneration research. 2022; 17(3): 618-624

Full-text options

Latest Statistics about COVID-19
• pubstat.org

Add your Article(s) to Indexes
• citeindex.org

Covid-19 Trends and Statistics
Follow ScopeMed on Twitter
Author Tools
eJPort Journal Hosting
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License (https://creativecommons.org/licenses/by-nc-sa/4.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.
ScopeMed is a Database Service for Scientific Publications. Copyright © ScopeMed® Information Services.

ScopeMed Web Sites